Akeso Inc

Price Chart

Risk-Adjusted Performance

Akeso Inc (9926) Price Performance

Akeso Inc (9926) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at HKD151.00, up 1.34% from the previous close.

Over the past year, 9926 has traded between a low of HKD75.00 and a high of HKD176.90. The stock has gained 70.8% over this period. It is currently 14.6% below its 52-week high.

Akeso Inc has a market capitalization of $134.39B.

About Akeso Inc

Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, and recurrent or refractory classical Hodgkin lymphoma; AK109, a PD-1 monoclonal antibody to treat G/GEJ patients; penpulimab, a PD-1 for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC); and tagitanlimab, a PD-L1 for treating recurrent or metastatic NPC. In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis. Further, its preclinical product includes AK120 to treat moderate-to-severe atopic dermatitis. Akeso, Inc. has collaboration with Inovio Pharmaceuticals, Inc. to evaluate INOVIO's INO-5412 in combination with cadonilimab as a potential treatment for glioblastoma (GBM). The company was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.